U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07393464) titled 'PQQ for Cognitive and Negative Symptoms' on Jan. 31.
Brief Summary: Schizophrenia is a complex mental disorder characterized by a range of symptoms, including negative symptoms and cognitive impairments. Recent research has indicated the potential benefits of targeting mitochondrial dysfunction, oxidative stress, and inflammatory responses in alleviating symptoms of schizophrenia. However, the results remain inconsistent across various studies. This study aims to evaluate the efficacy of Pyrroloquinoline quinone (PQQ) in reducing negative symptoms and improving cognitive function in patients with chronic schizophrenia. The investigat...